Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Medpage Today on MSN2d
NMO Drug Looks Good for IgG4-Related DiseaseWASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...
IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...
IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...
IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing ...
An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...
Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...
My name is Julianne, and I will be your conference facilitator today for Amgen's third-quarter 2024 financial results conference call. (Operator Instructions) I would now like to introduce Justin ...
which is in a phase 3 trial as a treatment for IgG4-related disease (IgG4-RD), phase 2/3 in warm autoimmune haemolytic anaemia (wAIHA), and phase 2 in multiple sclerosis (MS) and systemic lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback